Rhodes Pharmaceuticals L.P. today announced the launch of an authorized generic version of Aptensio XR® (methylphenidate hydrochloride extended-release) CII 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg capsules in the United States.
“We are pleased to bring an authorized generic of Aptensio XR® to market,” said Vince Mancinelli, President, Rhodes Pharmaceuticals. “This launch reinforces our commitment to providing patients with affordable, high-quality healthcare.”
For complete information about the use of Methylphenidate Hydrochloride Extended-Release Capsules, including important safety information, please refer to the FDA-approved Prescribing Information, including Boxed Warning, and Medication Guide posted on the NIH website at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7a7ffd1-bc30-4db8-8391-dddf76acd639.
WARNING: ABUSE AND DEPENDENCE
CNS stimulants, including Methylphenidate Hydrochloride Extended-Release Capsules, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Warning and Precautions (5.1), Drug Abuse and Dependence (9.2, 9.3)].
About Rhodes Pharmaceuticals L.P.
Rhodes Pharmaceuticals L.P. has developed and distributed quality pharmaceutical products nationwide since 2008. With our R&D capabilities, industry partnerships, broad customer base, and strong relationships with suppliers, we offer reliable supply of high-quality products at competitive prices. Rhodes is a wholly owned subsidiary of Purdue Pharma L.P. For more information about Rhodes Pharmaceuticals L.P. visit www.rhodespharma.com.